Surgery for infective endocarditis following low-intermediate risk transcatheter aortic valve replacement-a multicentre experience.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
15 06 2022
Historique:
received: 04 08 2021
revised: 04 01 2022
accepted: 27 01 2022
pubmed: 23 2 2022
medline: 8 7 2022
entrez: 22 2 2022
Statut: ppublish

Résumé

With the expansion of transcatheter aortic valve replacement (TAVR) into intermediate and low risk, the number of TAVR procedures is bound to rise and along with it the number of cases of infective endocarditis following TAVR (TIE). The aim of this study was to review a multicentre experience of patients undergoing surgical intervention for TIE and to analyse the underlying indications and operative results. We retrospectively identified and analysed 69 patients who underwent cardiac surgery due to TIE at 9 cardiac surgical departments across Germany. The primary outcome was operative mortality, 6-month and 1-year survival. Median age was 78 years (72-81) and 48(69.6%) were male. The median time to surgical aortic valve replacement was 14 months (5-24) after TAVR, with 32 patients (46.4%) being diagnosed with early TIE. Cardiac reoperations were performed in 17% of patients and 33% underwent concomitant mitral valve surgery. The main causative organisms were: Enterococcus faecalis (31.9%), coagulase-negative Staphylococcus spp. (26.1%), Methicillin-sensitive Staphylococcus aureus (15.9%) and viridians group streptococci (14.5%). Extracorporeal life support was required in 2 patients (2.9%) for a median duration of 3 days. Postoperative adverse cerebrovascular events were observed in 13 patients (18.9%). Postoperatively, 9 patients (13.0%) required a pacemaker and 33 patients (47.8%) needed temporary renal replacement therapy. Survival to discharge was 88.4% and survival at 6 months and 1 year was found to be 68% and 53%, respectively. Our results suggest that TIE can be treated according to the guidelines for prosthetic valve endocarditis, namely with early surgery. Surgery for TIE is associated with acceptable morbidity and mortality rates. Surgery should be discussed liberally as a treatment option in patients with TIE by the 'endocarditis team' in referral centres.

Identifiants

pubmed: 35190828
pii: 6534098
doi: 10.1093/ejcts/ezac075
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Shekhar Saha (S)

Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.
German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.

Dominik Joskowiak (D)

Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.
German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.

Mateo Marin-Cuartas (M)

University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany.

Mahmoud Diab (M)

Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.

Benedikt M Schwaiger (BM)

Department of Cardiac Surgery, Munich Municipal Hospital Bogenhausen, Technical University of Munich, Munich, Germany.

Rodrigo Sandoval-Boburg (R)

Department of Thoracic and Cardiovascular Surgery, Eberhard Karls University of Tübingen, Tübingen, Germany.

Aron-Frederik Popov (AF)

Department of Thoracic and Cardiovascular Surgery, Eberhard Karls University of Tübingen, Tübingen, Germany.

Carolyn Weber (C)

Department of Cardiothoracic Surgery, Heart Center of the University of Cologne, Cologne, Germany.

Sam Varghese (S)

Department of Cardiothoracic Surgery, Otto-von-Guericke University, Magdeburg, Germany.

Andreas Martens (A)

Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.

Serghei Cebotari (S)

Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.

Maximilian Scherner (M)

Department of Cardiothoracic Surgery, Otto-von-Guericke University, Magdeburg, Germany.

Walter Eichinger (W)

Department of Cardiac Surgery, Munich Municipal Hospital Bogenhausen, Technical University of Munich, Munich, Germany.

David Holzhey (D)

University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany.

Daniel-Sebastian Dohle (DS)

Department of Cardiovascular Surgery, University Hospital Mainz, Mainz, Germany.

Thorsten Wahlers (T)

Department of Cardiothoracic Surgery, Heart Center of the University of Cologne, Cologne, Germany.

Torsten Doenst (T)

Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.

Martin Misfeld (M)

University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany.
Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Institute of Academic Surgery, RPAH, Sydney, NSW, Australia.
The Baird Institute of Applied Heart and Lung Surgical Research, Sydney, Australia.
Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Julinda Mehilli (J)

Department of Cardiology, LMU University Hospital and German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.
Department of Cardiology, Medizinische Klinik I, Landshut-Achdorf Hospital, Landshut, Germany.

Steffen Massberg (S)

Department of Cardiology, LMU University Hospital and German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.

Christian Hagl (C)

Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.
German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH